RxDoctor Payments Data

Roman Tavarez, MD

Family Medicine · McAllen, TXNPI 1619129624

Payments from drug & device makers

$421,441in general payments, 2019–2025

Across 161 payments — averaging $2617.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$327K
  • Eli Lilly$93K
  • Novo Nordisk$929
  • Pfizer$169
  • Amgen$109
  • AbbVie$98
  • plus $502 from 12 others
$54,014in research payments, 2019–2025

Across 3 payments — averaging $18,005 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$54K

What the payments were for

  • Food & beverage$1,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421,441 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$153,510
Medicare patients
279
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide256$276,090
RybelsusSemaglutide44$75,146
JanuviaSitagliptin Phosphate63$65,168
TrulicityDulaglutide50$53,625
MounjaroTirzepatide39$40,550
Tresiba Flextouch U-200Insulin Degludec29$32,647
EliquisApixaban34$31,105
FarxigaDapagliflozin Propanediol45$29,530
JanumetSitagliptin Phos/Metformin Hcl27$26,691
Tresiba Flextouch U-100Insulin Degludec50$24,438
JardianceEmpagliflozin21$22,283
EntrestoSacubitril/Valsartan21$19,677
MyrbetriqMirabegron12$14,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,699
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$11,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$929$351,236300 claims
Lilly USA, LLCTrulicity, Mounjaro$70$94,17489 claims
PfizerEliquis$169$31,10534 claims
NovartisEntresto$55$19,67721 claims
Astellas Pharma US IncMyrbetriq$19$14,01812 claims
GSKTrelegy Ellipta$56$12,69917 claims
AbbVieLinzess, Synthroid$98$10,86532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →